» Articles » PMID: 32563270

Non-coding RNAs in Cancer: Platforms and Strategies for Investigating the Genomic "dark Matter"

Overview
Publisher Biomed Central
Specialty Oncology
Date 2020 Jun 22
PMID 32563270
Citations 100
Authors
Affiliations
Soon will be listed here.
Abstract

The discovery of the role of non-coding RNAs (ncRNAs) in the onset and progression of malignancies is a promising frontier of cancer genetics. It is clear that ncRNAs are candidates for therapeutic intervention, since they may act as biomarkers or key regulators of cancer gene network. Recently, profiling and sequencing of ncRNAs disclosed deep deregulation in human cancers mostly due to aberrant mechanisms of ncRNAs biogenesis, such as amplification, deletion, abnormal epigenetic or transcriptional regulation. Although dysregulated ncRNAs may promote hallmarks of cancer as oncogenes or antagonize them as tumor suppressors, the mechanisms behind these events remain to be clarified. The development of new bioinformatic tools as well as novel molecular technologies is a challenging opportunity to disclose the role of the "dark matter" of the genome. In this review, we focus on currently available platforms, computational analyses and experimental strategies to investigate ncRNAs in cancer. We highlight the differences among experimental approaches aimed to dissect miRNAs and lncRNAs, which are the most studied ncRNAs. These two classes indeed need different investigation taking into account their intrinsic characteristics, such as length, structures and also the interacting molecules. Finally, we discuss the relevance of ncRNAs in clinical practice by considering promises and challenges behind the bench to bedside translation.

Citing Articles

Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.

Benacka R, Szaboova D, Gulasova Z, Hertelyova Z Int J Mol Sci. 2025; 26(1.

PMID: 39795985 PMC: 11719911. DOI: 10.3390/ijms26010127.


Exploring the role of noncoding RNAs in cancer diagnosis, prognosis, and precision medicine.

Eldakhakhny B, Sutaih A, Siddiqui M, Aqeeli Y, Awan A, Alsayegh M Noncoding RNA Res. 2025; 9(4):1315-1323.

PMID: 39764154 PMC: 11703603. DOI: 10.1016/j.ncrna.2024.06.015.


LncRNA Expression Profiles in C6 Ceramide Treatment Reveal lnc_025370 as a Promoter in Canine Mammary Carcinoma CHMp Cells Progression.

Diao H, Zhao F, Wu M, Zhang Y, Tao Q, Chen S Curr Issues Mol Biol. 2024; 46(12):14190-14203.

PMID: 39727977 PMC: 11674213. DOI: 10.3390/cimb46120849.


Modeling ncRNA Synergistic Regulation in Cancer.

Zhang J, Xiong C, Wei X, Yang H, Zhao C Methods Mol Biol. 2024; 2883:377-402.

PMID: 39702718 DOI: 10.1007/978-1-0716-4290-0_17.


A Current Perspective of Medical Informatics Developments for a Clinical Translation of (Non-coding)RNAs and Single-Cell Technologies.

Baumann A, Ahmadi N, Wolfien M Methods Mol Biol. 2024; 2883:31-51.

PMID: 39702703 DOI: 10.1007/978-1-0716-4290-0_2.


References
1.
Emamjomeh A, Zahiri J, Asadian M, Behmanesh M, Fakheri B, Mahdevar G . Identification, Prediction and Data Analysis of Noncoding RNAs: A Review. Med Chem. 2018; 15(3):216-230. DOI: 10.2174/1573406414666181015151610. View

2.
Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

3.
He Q, Fang Y, Lu F, Pan J, Wang L, Gong W . Analysis of differential expression profile of miRNA in peripheral blood of patients with lung cancer. J Clin Lab Anal. 2019; 33(9):e23003. PMC: 6868404. DOI: 10.1002/jcla.23003. View

4.
Pirim H, Eksioglu B, Perkins A, Yuceer C . Clustering of High Throughput Gene Expression Data. Comput Oper Res. 2012; 39(12):3046-3061. PMC: 3491664. DOI: 10.1016/j.cor.2012.03.008. View

5.
La Russa M, Qi L . The New State of the Art: Cas9 for Gene Activation and Repression. Mol Cell Biol. 2015; 35(22):3800-9. PMC: 4609748. DOI: 10.1128/MCB.00512-15. View